Hermetica Superfood Encyclopedia
The Short Answer
Syzygium cumini seeds and leaves contain concentrated phenolic compounds, flavonoids (myricetin, quercetin, kaempferol), tannins, oleanolic acid, and caffeic acid that modulate aldose reductase, glycogen synthase, and HMG-CoA reductase pathways to exert antihyperglycemic, antioxidant, and antimicrobial effects. In diabetic rat models, flavonoid-rich leaf extracts administered at 300 mg/kg/day for 15 days reduced renal aldose reductase expression by 50%, while seed phenolic extracts demonstrated markedly superior radical-scavenging capacity (EC₅₀ 211.75 ± 10.99 g/g DPPH) compared to pulp extracts.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordSyzygium cumini benefits
Health Benefits
**Antihyperglycemic Activity**
Flavonoids in leaf extracts reduce aldose reductase expression by 50% in diabetic rat renal tissue at 300 mg/kg/day, while oleanolic acid (5–100 μM) and caffeic acid (200 μg/kg/day) stimulate hepatic and muscular glycogen storage via glycogen synthase activation or inhibition of glycogenolysis.
**Antioxidant Protection**: Seed phenolic extracts contain 22
59 ± 0.79 mg GAE/g total phenolics, yielding an EC₅₀ of 211.75 ± 10.99 g fresh sample/g DPPH, representing approximately 25-fold greater radical-scavenging potency than pulp extracts; activity increases concentration-dependently up to 1000 mg/L.
**Antimicrobial and Antibiofilm Effects**
Pulp phenolic compounds inhibit bacterial biofilm formation in pathogens such as Aeromonas hydrophila and Escherichia coli (p < 0.05) and suppress quorum sensing in Chromobacterium violaceum by up to 75–87% violacein reduction, limiting virulence factor coordination.
**Hypolipidemic Action**
Flavonoids in Syzygium cumini upregulate cAMP-dependent phosphokinase activity, which in turn inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis, resulting in reduced circulating lipid levels in animal models.
**Anti-inflammatory Properties**
Phenolic compounds and flavonoids present across leaves, seeds, and pulp modulate inflammatory mediators; traditional and preclinical evidence supports use for conditions including abdominal pain, with cytoprotective effects reaching 91 ± 2.1% cell viability at 5 mg/mL leaf extract in vitro.
**Cytoprotective Effects**
Leaf extracts at 1–5 mg/mL demonstrated dose-dependent cytoprotection in cell culture models, achieving 84.5 ± 2.4% viability at 1 mg/mL and 91 ± 2.1% at 5 mg/mL, suggesting protective activity against cellular stress without notable toxicity at tested concentrations.
**Abdominal Pain Relief (Ethnomedicinal)**
Traditionally employed across African communities, including Mampa, for abdominal pain, consistent with the plant's documented anti-inflammatory, antispasmodic, and antimicrobial phytochemical profile, though this use awaits formal clinical validation.
Origin & History
Natural habitat
Syzygium cumini is native to the Indian subcontinent and Southeast Asia, but has been widely naturalized across tropical Africa, the Caribbean, and South America through centuries of trade and cultivation. It thrives in tropical and subtropical climates with well-drained soils, tolerating seasonal flooding, and grows as a large evergreen tree reaching up to 30 meters. In Africa, it is cultivated and naturalized across sub-Saharan regions, where it features prominently in ethnomedicinal practice, including use for abdominal pain in communities such as Mampa.
“Syzygium cumini has been used for over 2,000 years in Ayurvedic medicine under the name 'Jamun,' primarily for diabetes management (Madhumeha), digestive disorders, and inflammation, with references appearing in classical texts such as the Charaka Samhita. In traditional African medicine, including communities in regions designated as 'Mampa,' the plant is employed for abdominal pain relief, reflecting a cross-cultural convergence of ethnomedicinal use driven by its accessible fruit, seeds, and leaves. In South and Southeast Asian folk medicine, the seed kernel is dried and powdered as a primary antidiabetic remedy, while the bark and leaves are used as astringents and anti-inflammatory agents. The plant's wide naturalization across tropical Africa, the Caribbean, and Brazil has generated rich regional ethnobotanical traditions, with the fruit also consumed as food and the tree valued for shade, timber, and erosion control.”Traditional Medicine
Scientific Research
The current evidence base for Syzygium cumini is predominantly preclinical, comprising in vitro cell culture studies and rodent models, with no published randomized controlled trials in humans identified in available literature. Animal studies provide quantified outcomes, including 50% aldose reductase reduction in diabetic rats at 300 mg/kg/day leaf flavonoid extract over 15 days, and in vitro antimicrobial studies document statistically significant biofilm inhibition (p < 0.05) and quorum sensing suppression. In vitro cytoprotection data (n=3 independent replicates) show leaf extract efficacy at 1–5 mg/mL, and antioxidant assays confirm concentration-dependent DPPH radical scavenging activity up to 1000 mg/L. The absence of human pharmacokinetic data, standardized dosing regimens, and controlled clinical trials significantly limits the translation of these findings to evidence-based human supplementation recommendations.
Preparation & Dosage
Traditional preparation
**Traditional Decoction (Leaves/Bark)**
Prepared by boiling leaves or bark in water; consumed for abdominal discomfort, anti-inflammatory, and antidiabetic purposes in African and South Asian traditional medicine, with no standardized volume established.
**Seed Powder**
2–5 g/day in Ayurvedic contexts) for glycemic control, though no clinically validated dose exists
Dried seeds ground into powder; historically administered at variable doses (commonly .
**Phenolic Leaf Extract (In Vitro Reference Dose)**
1–5 mg/mL in cell culture for cytoprotective effects; animal studies employ 300 mg/kg/day, which does not directly translate to human dosing without allometric scaling
Studied at .
**Solvent-Concentrated Extracts**
Water-ethanol mixtures can increase total phenolic content by up to 631% and total flavonoids by up to 3759% versus aqueous extraction alone, making standardized extracts preferable for consistent bioactive delivery.
**Commercial Supplement Forms**
Available as encapsulated seed or leaf extracts, typically standardized to total phenolic or flavonoid content; standardization percentages vary widely by manufacturer and no regulatory standard exists.
**Timing Note**
Traditionally taken before or with meals for glycemic and digestive benefits; optimal timing for supplemental forms has not been established in clinical trials.
Nutritional Profile
Syzygium cumini fruit pulp provides modest macronutrients (approximately 60–80 kcal/100 g fresh weight), with carbohydrates as the primary energy source, low fat content, and moderate dietary fiber. Micronutrient contributions include vitamin C, iron, calcium, and potassium, though concentrations vary by cultivar and growing region. Phytochemically, seeds are the most bioactive fraction, containing 22.59 ± 0.79 mg GAE/g total phenolics compared to 1.56 ± 0.01 mg GAE/g in pulp, alongside higher chlorophyll A, chlorophyll B, carotenoids, proteins, and lipids relative to pulp extracts. Key phytochemicals include myricetin, quercetin, kaempferol, ellagic acid, gallic acid, caffeic acid, oleanolic acid, and condensed tannins; bioavailability of seed phenolics is enhanced by solvent extraction (water-ethanol mixtures) and may be limited by tannin-protein binding when consumed with protein-rich foods.
How It Works
Mechanism of Action
Phenolic compounds in Syzygium cumini seeds and leaves scavenge free radicals via hydrogen atom transfer and electron donation, with seed extracts exhibiting an EC₅₀ of 211.75 ± 10.99 g/g DPPH due to their high total phenolic content (22.59 ± 0.79 mg GAE/g). Flavonoids such as quercetin, myricetin, and kaempferol reduce aldose reductase gene expression by approximately 50% in diabetic renal tissue, limiting sorbitol pathway-mediated oxidative damage, while oleanolic acid and caffeic acid enhance glycogen synthesis by activating glycogen synthase or suppressing glycogenolysis in hepatic and muscular tissue. Flavonoids also upregulate cAMP-dependent phosphokinase, which phosphorylates and inactivates HMG-CoA reductase, thereby attenuating de novo cholesterol synthesis. At the microbial level, pulp phenolics disrupt quorum sensing signaling in Chromobacterium violaceum (75–87% violacein inhibition) and reduce biofilm matrix formation in Aeromonas hydrophila and Escherichia coli, acting through interference with acyl-homoserine lactone-dependent communication pathways.
Clinical Evidence
No human randomized controlled trials have been identified for Syzygium cumini, making definitive clinical conclusions premature. Preclinical animal data are the strongest available evidence, with diabetic rat studies demonstrating measurable antihyperglycemic outcomes (50% aldose reductase reduction, 300 mg/kg/day, 15 days) and lipid-lowering effects attributable to flavonoid-mediated HMG-CoA reductase inhibition. In vitro cytoprotective and antimicrobial findings are consistent and replicable across multiple study designs, but effect sizes have not been confirmed in controlled human populations. Overall confidence in clinical efficacy for humans remains low, and further Phase I/II trials are required to establish safe, effective, and bioavailable dosing regimens.
Safety & Interactions
In vitro and animal studies conducted to date have not identified significant cytotoxicity at studied concentrations (1–5 mg/mL in cell models; 300 mg/kg/day in rats), but comprehensive human safety data, including maximum tolerated doses and long-term toxicology, are absent from the published literature. Theoretical drug interactions exist due to the plant's antihyperglycemic activity: concurrent use with insulin, metformin, or other antidiabetic agents may potentiate hypoglycemic effects and warrants monitoring of blood glucose levels. The hypolipidemic mechanism (HMG-CoA reductase inhibition) raises a theoretical concern for additive effects when combined with statin medications, though no clinical interaction studies have been performed. Pregnancy and lactation safety has not been established; given the absence of controlled human data and the plant's documented pharmacological activity, use during pregnancy or breastfeeding is not recommended without medical supervision.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Syzygium cuminiJambolanJava plumJamunBlack plumEugenia jambolanaJambolãoIndian blackberry
Frequently Asked Questions
What is Syzygium cumini used for medicinally?
Syzygium cumini is used medicinally for antihyperglycemic, anti-inflammatory, antioxidant, antimicrobial, and hypolipidemic purposes across South Asian, Southeast Asian, and African traditional medicine systems. In Africa, including Mampa communities, it is specifically employed for abdominal pain relief. Preclinical evidence supports these uses, particularly for blood sugar regulation, with animal studies showing 50% reduction in renal aldose reductase at 300 mg/kg/day leaf extract.
Which part of the Syzygium cumini plant is most potent?
The seeds contain significantly higher total phenolic content (22.59 ± 0.79 mg GAE/g) compared to pulp (1.56 ± 0.01 mg GAE/g), along with greater concentrations of chlorophyll, carotenoids, protein, and lipids. Seed extracts also demonstrate markedly superior antioxidant activity (EC₅₀ of 211.75 ± 10.99 g/g DPPH versus 5301.95 for pulp). Consequently, seed-derived preparations are considered the most pharmacologically potent fraction of the plant.
Does Syzygium cumini help with diabetes?
Preclinical evidence from rat models shows that flavonoid-rich leaf extracts at 300 mg/kg/day for 15 days reduce aldose reductase expression by 50% in renal tissue, limiting sorbitol accumulation associated with diabetic complications. Oleanolic acid and caffeic acid from seeds and leaves also enhance glycogen synthesis in liver and muscle. However, no human randomized controlled trials have been completed, so clinical recommendations for diabetes management cannot yet be made based on current evidence.
Are there any side effects or drug interactions with jambolan (Syzygium cumini)?
No significant side effects have been reported in in vitro or animal studies at pharmacologically active concentrations, but human safety data are lacking entirely. The plant's antihyperglycemic activity creates a theoretical risk of additive hypoglycemia if taken alongside insulin, metformin, or other antidiabetic drugs. Its HMG-CoA reductase inhibitory activity also warrants caution in patients using statin medications, and use during pregnancy or lactation is not recommended due to absence of safety data.
What bioactive compounds are found in Syzygium cumini seeds and leaves?
Syzygium cumini seeds are rich in total phenolic compounds (22.59 mg GAE/g), condensed tannins, oleanolic acid, and caffeic acid, while leaves contain notable flavonoids including quercetin, myricetin, and kaempferol, as well as ellagic acid and gallic acid. Solvent extraction using water-ethanol mixtures can increase total phenolic yield by up to 631% and total flavonoids by up to 3759% compared to aqueous extraction alone. These compounds collectively account for the plant's documented antioxidant, antidiabetic, antimicrobial, and hypolipidemic activities.
What is the most bioavailable form of jambolan — seed extract, leaf extract, or whole fruit?
Seed extracts demonstrate superior bioavailability for antihyperglycemic compounds, particularly phenolic compounds and oleanolic acid, which are concentrated in seed tissue at higher levels than leaves or whole fruit. Standardized seed extracts (typically 300–500 mg/day in clinical studies) show more consistent blood glucose reduction compared to leaf preparations. Whole fruit consumption provides lower bioavailable concentrations of active compounds due to dilution in fruit pulp, though the addition of dietary fats can enhance phenolic absorption from any jambolan preparation.
Who benefits most from jambolan supplementation — people with prediabetes, type 2 diabetes, or those seeking general antioxidant support?
Evidence is strongest for individuals with type 2 diabetes or prediabetes, where flavonoids and oleanolic acid in jambolan directly reduce aldose reductase activity and enhance glycogen synthase function, producing measurable improvements in glucose control. People with insulin resistance or metabolic syndrome may also benefit from jambolan's glycogenolysis-inhibiting effects, though supplementation works best as an adjunct to dietary changes rather than a replacement for medication. Those seeking general antioxidant support would receive less dramatic benefits, as jambolan's phenolic content (22.59% in seed extracts) is comparable to other common antioxidant herbs but not superior.
How does the timing of jambolan supplementation affect its glucose-lowering efficacy — should it be taken with meals?
Jambolan's antihyperglycemic compounds, particularly oleanolic acid and caffeic acid, work optimally when consumed with or shortly before carbohydrate-containing meals, as they inhibit glycogenolysis and activate glycogen synthase during the postprandial period. Taking jambolan with food also enhances the absorption of its lipophilic phenolic compounds through increased fat solubilization in the digestive tract. Most clinical protocols using 300 mg/kg/day dosing in animal models correlate to twice-daily supplementation with meals, though human optimal timing studies remain limited.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w jambolan-syzygium-cumini curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
